Supplementary Figure Legends

Supplementary Figure S1. Effects of AT13387 and imatinib on viability of GIST882, GIST430 and GIST48 cell lines.
GIST882, GIST430 and GIST48 cells were treated with 0.001 to 10 μM concentrations of AT13387 (●) or imatinib (□) for 7 days and cellular viability was measured with Alamar Blue. Each data point is mean ± SE of triplicate wells. The data are representative of at least two independent experiments.

Supplementary Figure S2. Effects of AT13387 and imatinib on pharmacodynamic markers of GIST-PSW tumors after multiple dosing.
GIST-PSW tumors on Day 22 of the efficacy study were analyzed for pharmacodynamic markers. Tumor-bearing animals were treated with AT13387 at 70 mg/kg intraperitoneally once a week for 4 weeks and imatinib at 50 mg/kg orally twice a day for 22 days. Animals were sacrificed 4 hours after the last dose. Immunoblots (A) were also analyzed by densitometry (B). Western immunoblot and densitometry analysis were performed as previously described (13;28).